Sellas Life Sciences (NASDAQ: SLS)
Sellas Life Sciences Group Inc (NASDAQ: SLS) is an immuno-pharmaceutical company. At the moment the company is in late stage clinical development with its flagship product, galinpepimut-S, also known as GPS.
GPS is being developed as a potential clinical option to treat various types of cancer. On June 19, 2019, the company announced that it received funding to move into a pivotal study of GPS as a result of a public offering of common stock and warrants.
Visit the Sellas Life Sciences investor relations website here.